UBE2A and Alzheimer disease: Further studies have shown that low CDR1as level can lead to the increased expression of miR-7 which downregulates the activity of ubiquitin conjugating enzyme E2 A (UBE2A), thereby resulting in impaired clearing of toxic amyloid peptides from brain in AD, suggesting that miR-7 may be a new target for AD treatment [36, 63].